nodes	percent_of_prediction	percent_of_DWPC	metapath
Atazanavir—SLCO1B3—Mycophenolate mofetil—systemic scleroderma	0.229	0.333	CbGbCtD
Atazanavir—SLCO1B3—Methotrexate—systemic scleroderma	0.0919	0.134	CbGbCtD
Atazanavir—ABCB1—Lisinopril—systemic scleroderma	0.0648	0.0944	CbGbCtD
Atazanavir—CYP2C9—Leflunomide—systemic scleroderma	0.0637	0.0928	CbGbCtD
Atazanavir—ABCC1—Methotrexate—systemic scleroderma	0.0635	0.0925	CbGbCtD
Atazanavir—ABCB1—Captopril—systemic scleroderma	0.0485	0.0707	CbGbCtD
Atazanavir—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0382	0.0556	CbGbCtD
Atazanavir—ABCB1—Prednisone—systemic scleroderma	0.0306	0.0445	CbGbCtD
Atazanavir—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0229	0.0333	CbGbCtD
Atazanavir—CYP3A4—Prednisone—systemic scleroderma	0.0183	0.0266	CbGbCtD
Atazanavir—ABCB1—Methotrexate—systemic scleroderma	0.0153	0.0223	CbGbCtD
Atazanavir—CYP2C9—cardial valve—systemic scleroderma	0.00522	0.71	CbGeAlD
Atazanavir—SLCO1B3—lung—systemic scleroderma	0.000646	0.0879	CbGeAlD
Atazanavir—ABCB1—blood vessel—systemic scleroderma	0.00033	0.0448	CbGeAlD
Atazanavir—ABCC1—tendon—systemic scleroderma	0.000285	0.0387	CbGeAlD
Atazanavir—ABCC1—lung—systemic scleroderma	0.00025	0.0339	CbGeAlD
Atazanavir—CYP2C9—digestive system—systemic scleroderma	0.000226	0.0307	CbGeAlD
Atazanavir—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000195	0.000638	CcSEcCtD
Atazanavir—Neutropenia—Prednisone—systemic scleroderma	0.000195	0.000637	CcSEcCtD
Atazanavir—Abdominal pain—Azathioprine—systemic scleroderma	0.000194	0.000636	CcSEcCtD
Atazanavir—Body temperature increased—Azathioprine—systemic scleroderma	0.000194	0.000636	CcSEcCtD
Atazanavir—Skin disorder—Lisinopril—systemic scleroderma	0.000194	0.000634	CcSEcCtD
Atazanavir—Malaise—Mycophenolate mofetil—systemic scleroderma	0.000193	0.000632	CcSEcCtD
Atazanavir—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000193	0.000631	CcSEcCtD
Atazanavir—Diarrhoea—Captopril—systemic scleroderma	0.000193	0.00063	CcSEcCtD
Atazanavir—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000193	0.00063	CcSEcCtD
Atazanavir—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000192	0.000628	CcSEcCtD
Atazanavir—Erectile dysfunction—Prednisone—systemic scleroderma	0.000192	0.000628	CcSEcCtD
Atazanavir—Feeling abnormal—Leflunomide—systemic scleroderma	0.000191	0.000626	CcSEcCtD
Atazanavir—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000191	0.000625	CcSEcCtD
Atazanavir—Fatigue—Mycophenolic acid—systemic scleroderma	0.000191	0.000625	CcSEcCtD
Atazanavir—Mood swings—Methotrexate—systemic scleroderma	0.000191	0.000624	CcSEcCtD
Atazanavir—Nausea—Mometasone—systemic scleroderma	0.00019	0.000623	CcSEcCtD
Atazanavir—Anorexia—Lisinopril—systemic scleroderma	0.00019	0.000622	CcSEcCtD
Atazanavir—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.00019	0.000621	CcSEcCtD
Atazanavir—Weight increased—Prednisone—systemic scleroderma	0.00019	0.00062	CcSEcCtD
Atazanavir—Constipation—Mycophenolic acid—systemic scleroderma	0.000189	0.000619	CcSEcCtD
Atazanavir—Pain—Mycophenolic acid—systemic scleroderma	0.000189	0.000619	CcSEcCtD
Atazanavir—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000189	0.000619	CcSEcCtD
Atazanavir—Weight decreased—Prednisone—systemic scleroderma	0.000188	0.000617	CcSEcCtD
Atazanavir—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000188	0.000616	CcSEcCtD
Atazanavir—Hyperglycaemia—Prednisone—systemic scleroderma	0.000188	0.000615	CcSEcCtD
Atazanavir—Cough—Mycophenolate mofetil—systemic scleroderma	0.000187	0.000611	CcSEcCtD
Atazanavir—Dizziness—Captopril—systemic scleroderma	0.000186	0.000609	CcSEcCtD
Atazanavir—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000186	0.000607	CcSEcCtD
Atazanavir—Depression—Prednisone—systemic scleroderma	0.000185	0.000606	CcSEcCtD
Atazanavir—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000185	0.000605	CcSEcCtD
Atazanavir—Urticaria—Leflunomide—systemic scleroderma	0.000184	0.000603	CcSEcCtD
Atazanavir—Body temperature increased—Leflunomide—systemic scleroderma	0.000184	0.0006	CcSEcCtD
Atazanavir—Abdominal pain—Leflunomide—systemic scleroderma	0.000184	0.0006	CcSEcCtD
Atazanavir—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000182	0.000597	CcSEcCtD
Atazanavir—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000182	0.000596	CcSEcCtD
Atazanavir—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000182	0.000596	CcSEcCtD
Atazanavir—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000182	0.000596	CcSEcCtD
Atazanavir—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000182	0.000596	CcSEcCtD
Atazanavir—Breast disorder—Methotrexate—systemic scleroderma	0.000182	0.000595	CcSEcCtD
Atazanavir—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000182	0.000594	CcSEcCtD
Atazanavir—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000182	0.000594	CcSEcCtD
Atazanavir—Hypersensitivity—Azathioprine—systemic scleroderma	0.000181	0.000592	CcSEcCtD
Atazanavir—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000181	0.000592	CcSEcCtD
Atazanavir—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000181	0.000592	CcSEcCtD
Atazanavir—Insomnia—Lisinopril—systemic scleroderma	0.00018	0.00059	CcSEcCtD
Atazanavir—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.00018	0.000589	CcSEcCtD
Atazanavir—Vomiting—Captopril—systemic scleroderma	0.000179	0.000586	CcSEcCtD
Atazanavir—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000178	0.000583	CcSEcCtD
Atazanavir—Dyspnoea—Lisinopril—systemic scleroderma	0.000178	0.000582	CcSEcCtD
Atazanavir—Rash—Captopril—systemic scleroderma	0.000178	0.000581	CcSEcCtD
Atazanavir—Dermatitis—Captopril—systemic scleroderma	0.000177	0.00058	CcSEcCtD
Atazanavir—Somnolence—Lisinopril—systemic scleroderma	0.000177	0.00058	CcSEcCtD
Atazanavir—Headache—Captopril—systemic scleroderma	0.000176	0.000577	CcSEcCtD
Atazanavir—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000176	0.000576	CcSEcCtD
Atazanavir—Dyspepsia—Lisinopril—systemic scleroderma	0.000176	0.000574	CcSEcCtD
Atazanavir—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000175	0.000573	CcSEcCtD
Atazanavir—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000175	0.000573	CcSEcCtD
Atazanavir—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000175	0.000572	CcSEcCtD
Atazanavir—Infection—Mycophenolate mofetil—systemic scleroderma	0.000174	0.000568	CcSEcCtD
Atazanavir—Decreased appetite—Lisinopril—systemic scleroderma	0.000173	0.000567	CcSEcCtD
Atazanavir—CYP3A4—digestive system—systemic scleroderma	0.000172	0.0234	CbGeAlD
Atazanavir—Eosinophilia—Methotrexate—systemic scleroderma	0.000172	0.000564	CcSEcCtD
Atazanavir—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000172	0.000563	CcSEcCtD
Atazanavir—Fatigue—Lisinopril—systemic scleroderma	0.000172	0.000563	CcSEcCtD
Atazanavir—Shock—Mycophenolate mofetil—systemic scleroderma	0.000172	0.000562	CcSEcCtD
Atazanavir—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000171	0.000561	CcSEcCtD
Atazanavir—Hypersensitivity—Leflunomide—systemic scleroderma	0.000171	0.000559	CcSEcCtD
Atazanavir—Pancreatitis—Methotrexate—systemic scleroderma	0.000171	0.000558	CcSEcCtD
Atazanavir—Constipation—Lisinopril—systemic scleroderma	0.000171	0.000558	CcSEcCtD
Atazanavir—Pain—Lisinopril—systemic scleroderma	0.000171	0.000558	CcSEcCtD
Atazanavir—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.00017	0.000555	CcSEcCtD
Atazanavir—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000169	0.000553	CcSEcCtD
Atazanavir—Diarrhoea—Azathioprine—systemic scleroderma	0.000168	0.00055	CcSEcCtD
Atazanavir—Nausea—Captopril—systemic scleroderma	0.000167	0.000547	CcSEcCtD
Atazanavir—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000167	0.000545	CcSEcCtD
Atazanavir—Asthenia—Leflunomide—systemic scleroderma	0.000167	0.000545	CcSEcCtD
Atazanavir—Hallucination—Prednisone—systemic scleroderma	0.000166	0.000543	CcSEcCtD
Atazanavir—Feeling abnormal—Lisinopril—systemic scleroderma	0.000164	0.000538	CcSEcCtD
Atazanavir—Pruritus—Leflunomide—systemic scleroderma	0.000164	0.000537	CcSEcCtD
Atazanavir—Connective tissue disorder—Prednisone—systemic scleroderma	0.000164	0.000536	CcSEcCtD
Atazanavir—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000163	0.000534	CcSEcCtD
Atazanavir—Neutropenia—Methotrexate—systemic scleroderma	0.000163	0.000533	CcSEcCtD
Atazanavir—Dizziness—Azathioprine—systemic scleroderma	0.000163	0.000532	CcSEcCtD
Atazanavir—Erectile dysfunction—Methotrexate—systemic scleroderma	0.00016	0.000525	CcSEcCtD
Atazanavir—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000159	0.000521	CcSEcCtD
Atazanavir—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000159	0.00052	CcSEcCtD
Atazanavir—Asthenia—Mycophenolic acid—systemic scleroderma	0.000159	0.00052	CcSEcCtD
Atazanavir—Diarrhoea—Leflunomide—systemic scleroderma	0.000159	0.00052	CcSEcCtD
Atazanavir—Urticaria—Lisinopril—systemic scleroderma	0.000158	0.000518	CcSEcCtD
Atazanavir—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000158	0.000517	CcSEcCtD
Atazanavir—Abdominal pain—Lisinopril—systemic scleroderma	0.000158	0.000516	CcSEcCtD
Atazanavir—Body temperature increased—Lisinopril—systemic scleroderma	0.000158	0.000516	CcSEcCtD
Atazanavir—Pruritus—Mycophenolic acid—systemic scleroderma	0.000157	0.000513	CcSEcCtD
Atazanavir—Vomiting—Azathioprine—systemic scleroderma	0.000156	0.000511	CcSEcCtD
Atazanavir—Eye disorder—Prednisone—systemic scleroderma	0.000156	0.00051	CcSEcCtD
Atazanavir—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000156	0.00051	CcSEcCtD
Atazanavir—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000155	0.000508	CcSEcCtD
Atazanavir—Rash—Azathioprine—systemic scleroderma	0.000155	0.000507	CcSEcCtD
Atazanavir—Dermatitis—Azathioprine—systemic scleroderma	0.000155	0.000507	CcSEcCtD
Atazanavir—Depression—Methotrexate—systemic scleroderma	0.000155	0.000506	CcSEcCtD
Atazanavir—Headache—Azathioprine—systemic scleroderma	0.000154	0.000504	CcSEcCtD
Atazanavir—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000154	0.000503	CcSEcCtD
Atazanavir—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000154	0.000503	CcSEcCtD
Atazanavir—Dizziness—Leflunomide—systemic scleroderma	0.000154	0.000502	CcSEcCtD
Atazanavir—Renal failure—Methotrexate—systemic scleroderma	0.000153	0.000499	CcSEcCtD
Atazanavir—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000152	0.000497	CcSEcCtD
Atazanavir—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000152	0.000496	CcSEcCtD
Atazanavir—Stomatitis—Methotrexate—systemic scleroderma	0.000151	0.000495	CcSEcCtD
Atazanavir—Angiopathy—Prednisone—systemic scleroderma	0.000151	0.000495	CcSEcCtD
Atazanavir—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000151	0.000494	CcSEcCtD
Atazanavir—Immune system disorder—Prednisone—systemic scleroderma	0.000151	0.000493	CcSEcCtD
Atazanavir—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000149	0.000489	CcSEcCtD
Atazanavir—Pain—Mycophenolate mofetil—systemic scleroderma	0.000149	0.000489	CcSEcCtD
Atazanavir—Sweating—Methotrexate—systemic scleroderma	0.000149	0.000487	CcSEcCtD
Atazanavir—Haematuria—Methotrexate—systemic scleroderma	0.000148	0.000484	CcSEcCtD
Atazanavir—Vomiting—Leflunomide—systemic scleroderma	0.000148	0.000483	CcSEcCtD
Atazanavir—Alopecia—Prednisone—systemic scleroderma	0.000147	0.000482	CcSEcCtD
Atazanavir—Hypersensitivity—Lisinopril—systemic scleroderma	0.000147	0.000481	CcSEcCtD
Atazanavir—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000147	0.00048	CcSEcCtD
Atazanavir—Dizziness—Mycophenolic acid—systemic scleroderma	0.000146	0.000479	CcSEcCtD
Atazanavir—Rash—Leflunomide—systemic scleroderma	0.000146	0.000479	CcSEcCtD
Atazanavir—Dermatitis—Leflunomide—systemic scleroderma	0.000146	0.000478	CcSEcCtD
Atazanavir—Mental disorder—Prednisone—systemic scleroderma	0.000146	0.000478	CcSEcCtD
Atazanavir—Nausea—Azathioprine—systemic scleroderma	0.000146	0.000478	CcSEcCtD
Atazanavir—Headache—Leflunomide—systemic scleroderma	0.000145	0.000476	CcSEcCtD
Atazanavir—Malnutrition—Prednisone—systemic scleroderma	0.000145	0.000475	CcSEcCtD
Atazanavir—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000144	0.000471	CcSEcCtD
Atazanavir—Asthenia—Lisinopril—systemic scleroderma	0.000143	0.000468	CcSEcCtD
Atazanavir—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000143	0.000467	CcSEcCtD
Atazanavir—Pruritus—Lisinopril—systemic scleroderma	0.000141	0.000462	CcSEcCtD
Atazanavir—Vomiting—Mycophenolic acid—systemic scleroderma	0.000141	0.000461	CcSEcCtD
Atazanavir—Rash—Mycophenolic acid—systemic scleroderma	0.00014	0.000457	CcSEcCtD
Atazanavir—Dermatitis—Mycophenolic acid—systemic scleroderma	0.00014	0.000456	CcSEcCtD
Atazanavir—Hepatitis—Methotrexate—systemic scleroderma	0.000139	0.000456	CcSEcCtD
Atazanavir—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000139	0.000454	CcSEcCtD
Atazanavir—Headache—Mycophenolic acid—systemic scleroderma	0.000139	0.000454	CcSEcCtD
Atazanavir—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000138	0.000452	CcSEcCtD
Atazanavir—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000138	0.000452	CcSEcCtD
Atazanavir—Nausea—Leflunomide—systemic scleroderma	0.000138	0.000451	CcSEcCtD
Atazanavir—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000138	0.00045	CcSEcCtD
Atazanavir—Urethral disorder—Methotrexate—systemic scleroderma	0.000137	0.000447	CcSEcCtD
Atazanavir—Diarrhoea—Lisinopril—systemic scleroderma	0.000136	0.000446	CcSEcCtD
Atazanavir—Ill-defined disorder—Prednisone—systemic scleroderma	0.000135	0.000441	CcSEcCtD
Atazanavir—Agitation—Prednisone—systemic scleroderma	0.000133	0.000436	CcSEcCtD
Atazanavir—Angioedema—Prednisone—systemic scleroderma	0.000133	0.000434	CcSEcCtD
Atazanavir—Dizziness—Lisinopril—systemic scleroderma	0.000132	0.000431	CcSEcCtD
Atazanavir—Erythema multiforme—Methotrexate—systemic scleroderma	0.000132	0.000431	CcSEcCtD
Atazanavir—Nausea—Mycophenolic acid—systemic scleroderma	0.000132	0.00043	CcSEcCtD
Atazanavir—Malaise—Prednisone—systemic scleroderma	0.000131	0.000428	CcSEcCtD
Atazanavir—Eye disorder—Methotrexate—systemic scleroderma	0.00013	0.000426	CcSEcCtD
Atazanavir—Syncope—Prednisone—systemic scleroderma	0.00013	0.000426	CcSEcCtD
Atazanavir—Tinnitus—Methotrexate—systemic scleroderma	0.00013	0.000425	CcSEcCtD
Atazanavir—Cardiac disorder—Methotrexate—systemic scleroderma	0.000129	0.000423	CcSEcCtD
Atazanavir—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000129	0.000421	CcSEcCtD
Atazanavir—Loss of consciousness—Prednisone—systemic scleroderma	0.000128	0.000417	CcSEcCtD
Atazanavir—Vomiting—Lisinopril—systemic scleroderma	0.000127	0.000415	CcSEcCtD
Atazanavir—Angiopathy—Methotrexate—systemic scleroderma	0.000126	0.000414	CcSEcCtD
Atazanavir—Immune system disorder—Methotrexate—systemic scleroderma	0.000126	0.000412	CcSEcCtD
Atazanavir—Rash—Lisinopril—systemic scleroderma	0.000126	0.000411	CcSEcCtD
Atazanavir—Convulsion—Prednisone—systemic scleroderma	0.000126	0.000411	CcSEcCtD
Atazanavir—Dermatitis—Lisinopril—systemic scleroderma	0.000126	0.000411	CcSEcCtD
Atazanavir—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000126	0.000411	CcSEcCtD
Atazanavir—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000125	0.00041	CcSEcCtD
Atazanavir—Hypertension—Prednisone—systemic scleroderma	0.000125	0.00041	CcSEcCtD
Atazanavir—Headache—Lisinopril—systemic scleroderma	0.000125	0.000409	CcSEcCtD
Atazanavir—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000124	0.000404	CcSEcCtD
Atazanavir—Myalgia—Prednisone—systemic scleroderma	0.000124	0.000404	CcSEcCtD
Atazanavir—Arthralgia—Prednisone—systemic scleroderma	0.000124	0.000404	CcSEcCtD
Atazanavir—Anxiety—Prednisone—systemic scleroderma	0.000123	0.000403	CcSEcCtD
Atazanavir—Alopecia—Methotrexate—systemic scleroderma	0.000123	0.000403	CcSEcCtD
Atazanavir—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000123	0.000401	CcSEcCtD
Atazanavir—Discomfort—Prednisone—systemic scleroderma	0.000122	0.000399	CcSEcCtD
Atazanavir—Mental disorder—Methotrexate—systemic scleroderma	0.000122	0.000399	CcSEcCtD
Atazanavir—ABCB1—digestive system—systemic scleroderma	0.000122	0.0166	CbGeAlD
Atazanavir—Malnutrition—Methotrexate—systemic scleroderma	0.000121	0.000397	CcSEcCtD
Atazanavir—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.00012	0.000391	CcSEcCtD
Atazanavir—Dysgeusia—Methotrexate—systemic scleroderma	0.000119	0.000389	CcSEcCtD
Atazanavir—Nausea—Lisinopril—systemic scleroderma	0.000118	0.000388	CcSEcCtD
Atazanavir—Oedema—Prednisone—systemic scleroderma	0.000118	0.000388	CcSEcCtD
Atazanavir—Infection—Prednisone—systemic scleroderma	0.000118	0.000385	CcSEcCtD
Atazanavir—Back pain—Methotrexate—systemic scleroderma	0.000117	0.000384	CcSEcCtD
Atazanavir—Shock—Prednisone—systemic scleroderma	0.000117	0.000381	CcSEcCtD
Atazanavir—Nervous system disorder—Prednisone—systemic scleroderma	0.000116	0.00038	CcSEcCtD
Atazanavir—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000116	0.000378	CcSEcCtD
Atazanavir—Skin disorder—Prednisone—systemic scleroderma	0.000115	0.000376	CcSEcCtD
Atazanavir—Hyperhidrosis—Prednisone—systemic scleroderma	0.000115	0.000375	CcSEcCtD
Atazanavir—Anorexia—Prednisone—systemic scleroderma	0.000113	0.000369	CcSEcCtD
Atazanavir—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000113	0.000368	CcSEcCtD
Atazanavir—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000111	0.000363	CcSEcCtD
Atazanavir—Rash—Mycophenolate mofetil—systemic scleroderma	0.00011	0.00036	CcSEcCtD
Atazanavir—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.00011	0.00036	CcSEcCtD
Atazanavir—Headache—Mycophenolate mofetil—systemic scleroderma	0.000109	0.000358	CcSEcCtD
Atazanavir—Malaise—Methotrexate—systemic scleroderma	0.000109	0.000358	CcSEcCtD
Atazanavir—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000108	0.000353	CcSEcCtD
Atazanavir—Insomnia—Prednisone—systemic scleroderma	0.000107	0.00035	CcSEcCtD
Atazanavir—Cough—Methotrexate—systemic scleroderma	0.000106	0.000346	CcSEcCtD
Atazanavir—Convulsion—Methotrexate—systemic scleroderma	0.000105	0.000344	CcSEcCtD
Atazanavir—Dyspepsia—Prednisone—systemic scleroderma	0.000104	0.000341	CcSEcCtD
Atazanavir—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000104	0.00034	CcSEcCtD
Atazanavir—Chest pain—Methotrexate—systemic scleroderma	0.000103	0.000338	CcSEcCtD
Atazanavir—Myalgia—Methotrexate—systemic scleroderma	0.000103	0.000338	CcSEcCtD
Atazanavir—Arthralgia—Methotrexate—systemic scleroderma	0.000103	0.000338	CcSEcCtD
Atazanavir—Decreased appetite—Prednisone—systemic scleroderma	0.000103	0.000337	CcSEcCtD
Atazanavir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000103	0.000336	CcSEcCtD
Atazanavir—Fatigue—Prednisone—systemic scleroderma	0.000102	0.000334	CcSEcCtD
Atazanavir—Discomfort—Methotrexate—systemic scleroderma	0.000102	0.000334	CcSEcCtD
Atazanavir—ABCB1—lung—systemic scleroderma	0.000102	0.0139	CbGeAlD
Atazanavir—Constipation—Prednisone—systemic scleroderma	0.000101	0.000331	CcSEcCtD
Atazanavir—Confusional state—Methotrexate—systemic scleroderma	9.98e-05	0.000327	CcSEcCtD
Atazanavir—Infection—Methotrexate—systemic scleroderma	9.84e-05	0.000322	CcSEcCtD
Atazanavir—Feeling abnormal—Prednisone—systemic scleroderma	9.76e-05	0.000319	CcSEcCtD
Atazanavir—Nervous system disorder—Methotrexate—systemic scleroderma	9.71e-05	0.000318	CcSEcCtD
Atazanavir—Gastrointestinal pain—Prednisone—systemic scleroderma	9.69e-05	0.000317	CcSEcCtD
Atazanavir—Skin disorder—Methotrexate—systemic scleroderma	9.62e-05	0.000315	CcSEcCtD
Atazanavir—Hyperhidrosis—Methotrexate—systemic scleroderma	9.57e-05	0.000313	CcSEcCtD
Atazanavir—Anorexia—Methotrexate—systemic scleroderma	9.44e-05	0.000309	CcSEcCtD
Atazanavir—Urticaria—Prednisone—systemic scleroderma	9.41e-05	0.000308	CcSEcCtD
Atazanavir—Abdominal pain—Prednisone—systemic scleroderma	9.37e-05	0.000306	CcSEcCtD
Atazanavir—Body temperature increased—Prednisone—systemic scleroderma	9.37e-05	0.000306	CcSEcCtD
Atazanavir—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	9.02e-05	0.000295	CcSEcCtD
Atazanavir—Insomnia—Methotrexate—systemic scleroderma	8.95e-05	0.000293	CcSEcCtD
Atazanavir—Dyspnoea—Methotrexate—systemic scleroderma	8.83e-05	0.000289	CcSEcCtD
Atazanavir—Somnolence—Methotrexate—systemic scleroderma	8.8e-05	0.000288	CcSEcCtD
Atazanavir—Hypersensitivity—Prednisone—systemic scleroderma	8.73e-05	0.000286	CcSEcCtD
Atazanavir—Dyspepsia—Methotrexate—systemic scleroderma	8.72e-05	0.000285	CcSEcCtD
Atazanavir—Decreased appetite—Methotrexate—systemic scleroderma	8.61e-05	0.000282	CcSEcCtD
Atazanavir—Gastrointestinal disorder—Methotrexate—systemic scleroderma	8.55e-05	0.00028	CcSEcCtD
Atazanavir—Fatigue—Methotrexate—systemic scleroderma	8.54e-05	0.000279	CcSEcCtD
Atazanavir—Asthenia—Prednisone—systemic scleroderma	8.5e-05	0.000278	CcSEcCtD
Atazanavir—Pain—Methotrexate—systemic scleroderma	8.47e-05	0.000277	CcSEcCtD
Atazanavir—Pruritus—Prednisone—systemic scleroderma	8.38e-05	0.000274	CcSEcCtD
Atazanavir—Feeling abnormal—Methotrexate—systemic scleroderma	8.16e-05	0.000267	CcSEcCtD
Atazanavir—Diarrhoea—Prednisone—systemic scleroderma	8.11e-05	0.000265	CcSEcCtD
Atazanavir—Gastrointestinal pain—Methotrexate—systemic scleroderma	8.1e-05	0.000265	CcSEcCtD
Atazanavir—Urticaria—Methotrexate—systemic scleroderma	7.87e-05	0.000257	CcSEcCtD
Atazanavir—Dizziness—Prednisone—systemic scleroderma	7.83e-05	0.000256	CcSEcCtD
Atazanavir—Abdominal pain—Methotrexate—systemic scleroderma	7.83e-05	0.000256	CcSEcCtD
Atazanavir—Body temperature increased—Methotrexate—systemic scleroderma	7.83e-05	0.000256	CcSEcCtD
Atazanavir—Vomiting—Prednisone—systemic scleroderma	7.53e-05	0.000246	CcSEcCtD
Atazanavir—Rash—Prednisone—systemic scleroderma	7.47e-05	0.000244	CcSEcCtD
Atazanavir—Dermatitis—Prednisone—systemic scleroderma	7.46e-05	0.000244	CcSEcCtD
Atazanavir—Headache—Prednisone—systemic scleroderma	7.42e-05	0.000243	CcSEcCtD
Atazanavir—Hypersensitivity—Methotrexate—systemic scleroderma	7.29e-05	0.000239	CcSEcCtD
Atazanavir—Asthenia—Methotrexate—systemic scleroderma	7.1e-05	0.000232	CcSEcCtD
Atazanavir—Nausea—Prednisone—systemic scleroderma	7.04e-05	0.00023	CcSEcCtD
Atazanavir—Pruritus—Methotrexate—systemic scleroderma	7e-05	0.000229	CcSEcCtD
Atazanavir—Diarrhoea—Methotrexate—systemic scleroderma	6.77e-05	0.000222	CcSEcCtD
Atazanavir—Dizziness—Methotrexate—systemic scleroderma	6.55e-05	0.000214	CcSEcCtD
Atazanavir—Vomiting—Methotrexate—systemic scleroderma	6.3e-05	0.000206	CcSEcCtD
Atazanavir—Rash—Methotrexate—systemic scleroderma	6.24e-05	0.000204	CcSEcCtD
Atazanavir—Dermatitis—Methotrexate—systemic scleroderma	6.24e-05	0.000204	CcSEcCtD
Atazanavir—Headache—Methotrexate—systemic scleroderma	6.2e-05	0.000203	CcSEcCtD
Atazanavir—Nausea—Methotrexate—systemic scleroderma	5.88e-05	0.000192	CcSEcCtD
